Vera Therapeutics, Inc. (VERA)
| Market Cap | 2.46B +75.3% |
| Revenue (ttm) | n/a |
| Net Income | -401.90M |
| EPS | -5.89 |
| Shares Out | 72.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,257,469 |
| Open | 34.40 |
| Previous Close | 34.60 |
| Day's Range | 33.34 - 34.47 |
| 52-Week Range | 21.20 - 56.05 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 77.14 (+125.62%) |
| Earnings Date | Aug 10, 2026 |
About VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for VERA stock is "Strong Buy." The 12-month stock price target is $77.14, which is an increase of 125.62% from the latest price.
News
3 Best Stocks With 100%+ Upside to Buy This Week, According to Analysts
Analysts see strong momentum in some stocks this week, including Fervo Energy ($FRVO), Vera Therapeutics ($VERA), and Hut 8 ($HUT). While each stock carries risk, analysts believe all three have more…
Vera Therapeutics price target lowered to $90 from $125 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Vera Therapeutics (VERA) to $90 from $125 and keeps a Buy rating on the shares. The firm reduced peak revenue projections for…
Vera Therapeutics price target raised to $84 from $78 at Raymond James
Raymond James analyst Ryan Deschner raised the firm’s price target on Vera Therapeutics (VERA) to $84 from $78 and keeps a Strong Buy rating on the shares. Vera’s Trutakna launch…
Vera Therapeutics price target lowered to $34 from $43 at Wedbush
Wedbush lowered the firm’s price target on Vera Therapeutics (VERA) to $34 from $43 and keeps a Neutral rating on the shares. With Trutakna launching in July, the firm sees…
Vera Therapeutics price target lowered to $66 from $70 at BofA
BofA lowered the firm’s price target on Vera Therapeutics (VERA) to $66 from $70 and keeps a Buy rating on the shares. The firm updated its model for Q2, decreased…
Vera Therapeutics reports Q3 EPS ($1.52), consensus ($1.59)
“The accelerated approval and commercial launch of TRUTAKNA represent transformative milestones for Vera Therapeutics (VERA) and are the result of years of hard work and dedication. We are extremely g...
Vera Therapeutics Earnings release: Q2 2026
Vera Therapeutics released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Vera Therapeutics Quarterly report: Q2 2026
Vera Therapeutics has published its Q2 2026 quarterly earnings report on August 10, 2026.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 3, 2026, the Compensation Committee of the Board of Directors (Compensation C...
Vera chief regulatory officer William Turner to retire, Nancy Boman to succeed
Vera Therapeutics (VERA) announced a planned transition of the chief regulatory officer position. William Turner, current chief regulatory officer of Vera Therapeutics, is planning to retire and trans...
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Offic...
Vera Therapeutics price target raised to $76 from $56 at Guggenheim
Guggenheim raised the firm’s price target on Vera Therapeutics (VERA) to $76 from $56 and keeps a Buy rating on the shares. Following Trutakna’s FDA approval, the outlook on Vera…
Vera Therapeutics price target raised to $78 from $73 at TD Cowen
TD Cowen raised the firm’s price target on Vera Therapeutics (VERA) to $78 from $73 and keeps a Buy rating on the shares. The firm noted Trutakna (atacicept 150mg SC)…
Vera Therapeutics price target raised to $43 from $35 at Wedbush
Wedbush raised the firm’s price target on Vera Therapeutics (VERA) to $43 from $35 and keeps a Neutral rating on the shares. The firm is increasing its gross/net pricing for…
Vera Therapeutics price target raised to $125 from $110 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Vera Therapeutics (VERA) to $125 from $110 and keeps a Buy rating on the shares after the FDA granted accelerated approval to…
Vera Therapeutics Transcript: FDA announcement
FDA granted accelerated approval to TRUTAKNA for adults with IgA nephropathy, based on robust Phase III data showing significant proteinuria reduction and a favorable safety profile. The product will be available within weeks, with a trained sales force and broad payer support.
Vera Therapeutics Press release: FDA announcement
Vera Therapeutics issued a press release on July 7, 2026, disclosing material business information to investors.
Vera Therapeutics price target raised to $70 from $65 at BofA
BofA raised the firm’s price target on Vera Therapeutics (VERA) to $70 from $65 and keeps a Buy rating on the shares following Trutakna’s conditional FDA approval for the treatment…
US FDA approves Vera's kidney disease drug
The U.S. Food and Drug Administration has approved Vera Therapeutics' drug to treat patients with a potentially life-threatening kidney disease, the regulator said on Tuesday, sending its shares...
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA ...
Vera Therapeutics Slides: Corporate presentation
Vera Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis
Vera Therapeutics (VERA) announced it has aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan to support full approval for atacicept in…
Raymond James sees unique buying opportunity in Vera after FDA alignment
Raymond James notes Strong Buy-rated Vera Therapeutics (VERA) announced it has alignment with FDA to carry out an earlier Phase 3 eGFR analysis to potentially support full approval for atacicept…
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgAN
Vera Therapeutics Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved by shareholders. No questions were raised, and quorum was confirmed. Final voting results will be filed on Form 8-K.